

Marina Sagud

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2212641/publications.pdf>

Version: 2024-02-01

72
papers

1,578
citations

304743

22
h-index

330143

37
g-index

74
all docs

74
docs citations

74
times ranked

2017
citing authors

#	ARTICLE	IF	CITATIONS
1	The association between BDNF C270T genetic variants and smoking in patients with mental disorders and in healthy controls. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 113, 110452.	4.8	2
2	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86.	3.3	107
3	Physical and social anhedonia are associated with suicidality in major depression, but not in schizophrenia. <i>Suicide and Life-Threatening Behavior</i> , 2021, 51, 446-454.	1.9	22
4	Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 105, 110016.	4.8	21
5	ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 104, 110042.	4.8	9
6	Depression: Biological markers and treatment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 105, 110139.	4.8	46
7	A Load to Find Clinically Useful Biomarkers for Depression. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1305, 175-202.	1.6	4
8	Distinct association of plasma BDNF concentration and cognitive function in depressed patients treated with vortioxetine or escitalopram. <i>Psychopharmacology</i> , 2021, 238, 1575-1584.	3.1	8
9	Moderating Effects of BDNF Genetic Variants and Smoking on Cognition in PTSD Veterans. <i>Biomolecules</i> , 2021, 11, 641.	4.0	6
10	Personalized treatment interventions: nonpharmacological and natural treatment strategies in Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 571-589.	2.8	10
11	Understanding Emotions: Origins and Roles of the Amygdala. <i>Biomolecules</i> , 2021, 11, 823.	4.0	95
12	Personalizing the Care and Treatment of Alzheimer's Disease: An Overview. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 631-653.	0.7	3
13	The Associations between COMT and MAO-B Genetic Variants with Negative Symptoms in Patients with Schizophrenia. <i>Current Issues in Molecular Biology</i> , 2021, 43, 618-636.	2.4	14
14	Symptom continuum reported by affective disorder patients through a structure-validated questionnaire. <i>BMC Psychiatry</i> , 2020, 20, 207.	2.6	1
15	Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia. <i>Scientific Reports</i> , 2020, 10, 10049.	3.3	13
16	HTR1A, HTR1B, HTR2A, HTR2C and HTR6 Gene Polymorphisms and Extrapyramidal Side Effects in Haloperidol-Treated Patients with Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2345.	4.1	16
17	Temperament, Character, and Subjective Well-Being in Croatian War Veterans Suffering From Posttraumatic Stress Disorder. <i>Journal of Nervous and Mental Disease</i> , 2020, 208, 340-343.	1.0	2
18	REMISSION IS NOT ASSOCIATED WITH DRD2 RS1800497 AND DAT1 RS28363170 GENETIC VARIANTS IN MALE SCHIZOPHRENIC PATIENTS AFTER 6-MONTHS MONOTHERAPY WITH OLANZAPINE. <i>Psychiatria Danubina</i> , 2020, 32, 84-91.	0.4	2

#	ARTICLE	IF	CITATIONS
19	Utilization of somatic healthcare in Croatian patients with schizophrenia spectrum disorder, major depression, PTSD and the general population. <i>BMC Psychiatry</i> , 2019, 19, 203.	2.6	3
20	The lack of association between COMT rs4680 polymorphism and symptomatic remission to olanzapine monotherapy in male schizophrenic patients: A longitudinal study. <i>Psychiatry Research</i> , 2019, 279, 389-390.	3.3	1
21	Smoking in schizophrenia. <i>Current Opinion in Psychiatry</i> , 2019, 32, 402-408.	6.3	57
22	Religiosity and Severity of Symptoms in Croatian Patients With Major Depressive Disorder or Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2019, 207, 515-522.	1.0	3
23	Genetic Markers in Psychiatry. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1192, 53-93.	1.6	2
24	INTEGRATION OF COMPLEMENTARY BIOMARKERS IN PATIENTS WITH FIRST EPISODE PSYCHOSIS: RESEARCH PROTOCOL OF A PROSPECTIVE FOLLOW UP STUDY. <i>Psychiatria Danubina</i> , 2019, 31, 162-171.	0.4	8
25	Anhedonia in Schizophrenia: Mini-Review. <i>Psychiatria Danubina</i> , 2019, 31, 143-147.	0.4	4
26	Latent <i>Toxoplasma gondii</i> infection is associated with decreased serum triglyceride to high-density lipoprotein cholesterol ratio in male patients with schizophrenia. <i>Comprehensive Psychiatry</i> , 2018, 82, 115-120.	3.1	6
27	The Effects of Electroconvulsive Therapy Augmentation of Antipsychotic Treatment on Cognitive Functions in Patients With Treatment-Resistant Schizophrenia. <i>Journal of ECT</i> , 2018, 34, 31-34.	0.6	20
28	Increased prevalence of <i>Toxoplasma gondii</i> seropositivity in patients with treatment-resistant schizophrenia. <i>Schizophrenia Research</i> , 2018, 193, 480-481.	2.0	12
29	Genetic Variants of the Brain-Derived Neurotrophic Factor and Metabolic Indices in Veterans With Posttraumatic Stress Disorder. <i>Frontiers in Psychiatry</i> , 2018, 9, 637.	2.6	16
30	The relationship among psychopathology, religiosity, and nicotine dependence in Croatian war veterans with posttraumatic stress disorder. <i>Croatian Medical Journal</i> , 2018, 59, 165-177.	0.7	8
31	Haplotypic and Genotypic Association of Catechol-O-Methyltransferase rs4680 and rs4818 Polymorphisms and Treatment Resistance in Schizophrenia. <i>Frontiers in Pharmacology</i> , 2018, 9, 705.	3.5	26
32	Nicotine dependence in Croatian male inpatients with schizophrenia. <i>BMC Psychiatry</i> , 2018, 18, 18.	2.6	19
33	Smoking in Schizophrenia: an Updated Review. <i>Psychiatria Danubina</i> , 2018, 30, 216-223.	0.4	19
34	Increased prevalence of <i>Toxoplasma gondii</i> seropositivity in patients with treatment-resistant schizophrenia. <i>European Psychiatry</i> , 2017, 41, s834-s834.	0.2	0
35	Brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study. <i>Nordic Journal of Psychiatry</i> , 2017, 71, 513-520.	1.3	18
36	CARDIOVASCULAR DISEASE RISK FACTORS IN PATIENTS WITH POSTTRAUMATIC STRESS DISORDER (PTSD): A NARRATIVE REVIEW. <i>Psychiatria Danubina</i> , 2017, 29, 421-430.	0.4	18

#	ARTICLE	IF	CITATIONS
37	A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment. <i>Psychopharmacology</i> , 2016, 233, 3259-3267.	3.1	30
38	Olanzapine Long-Acting Injections After Neuroleptic Malignant Syndrome. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 733-735.	1.4	2
39	Treatment-resistant schizophrenia: challenges and implications for clinical practice. <i>Psychiatria Danubina</i> , 2015, 27, 319-26.	0.4	8
40	Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients. <i>Psychopharmacology</i> , 2014, 231, 3757-3764.	3.1	28
41	Predicting symptom clusters of posttraumatic stress disorder (PTSD) in Croatian war veterans: the role of socio-demographics, war experiences and subjective quality of life. <i>Psychiatria Danubina</i> , 2014, 26, 231-8.	0.4	8
42	The lack of association between components of metabolic syndrome and treatment resistance in depression. <i>Psychopharmacology</i> , 2013, 230, 15-21.	3.1	25
43	The lack of association between catechol-O-methyl-transferase Val108/158Met polymorphism and smoking in schizophrenia and alcohol dependence. <i>Psychiatry Research</i> , 2013, 205, 179-180.	3.3	12
44	The Association Study of Polymorphisms in DAT, DRD2, and COMT Genes and Acute Extrapyramidal Adverse Effects in Male Schizophrenic Patients Treated With Haloperidol. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 593-599.	1.4	35
45	Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophrenia. <i>Nordic Journal of Psychiatry</i> , 2013, 67, 320-325.	1.3	42
46	Antipsychotics: to combine or not to combine?. <i>Psychiatria Danubina</i> , 2013, 25, 306-10.	0.4	8
47	Antipsychotics do not affect platelet serotonin in schizophrenic patients. <i>Translational Neuroscience</i> , 2012, 3, 56-60.	1.4	1
48	The lack of effect of ziprasidone on platelet serotonin concentration in schizophrenic patients. <i>Psychopharmacology</i> , 2012, 219, 1179-1181.	3.1	1
49	Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with second generation antipsychotics. <i>Psychiatry Research</i> , 2011, 189, 21-25.	3.3	36
50	Baseline Lipid Levels and Acute Treatment Response to Paroxetine and Tianeptine in Depressed Women. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 387-390.	1.4	2
51	Do we need new therapeutic strategies for depression?. <i>Psychiatria Danubina</i> , 2011, 23, 300-1.	0.4	5
52	Antipsychotics as antidepressants: what is the mechanism?. <i>Psychiatria Danubina</i> , 2011, 23, 302-7.	0.4	19
53	Catechol-O-methyl transferase and schizophrenia. <i>Psychiatria Danubina</i> , 2010, 22, 270-4.	0.4	32
54	Lipid levels in female patients with affective disorders. <i>Psychiatry Research</i> , 2009, 168, 218-221.	3.3	42

#	ARTICLE	IF	CITATIONS
55	Smoking and schizophrenia. <i>Psychiatria Danubina</i> , 2009, 21, 371-5.	0.4	77
56	The effect of lamotrigine on platelet serotonin concentration in patients with bipolar depression. <i>Psychopharmacology</i> , 2008, 197, 683-685.	3.1	9
57	The effect of lamotrigine on platelet monoamine oxidase type B activity in patients with bipolar depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1195-1198.	4.8	17
58	MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1439-1444.	4.8	62
59	Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. <i>World Journal of Biological Psychiatry</i> , 2008, 9, 190-197.	2.6	36
60	Genetics of schizophrenia in the context of integrative psychiatry. <i>Psychiatria Danubina</i> , 2008, 20, 364-8.	0.4	0
61	Platelet serotonin and serum lipids in psychotic mania. <i>Journal of Affective Disorders</i> , 2007, 97, 247-251.	4.1	23
62	Quetiapine augmentation in treatment-resistant depression: a naturalistic study. <i>Psychopharmacology</i> , 2006, 187, 511-514.	3.1	34
63	Serotonin transporter polymorphism in Croatian patients with major depressive disorder. <i>Psychiatria Danubina</i> , 2006, 18, 83-9.	0.4	14
64	Comorbid Depression and Platelet Serotonin in Hemodialysis Patients. <i>Nephron Clinical Practice</i> , 2004, 96, c10-c14.	2.3	10
65	Platelet serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women. <i>Psychiatry Research</i> , 2004, 127, 217-226.	3.3	87
66	Platelet 5-HT concentration and comorbid depression in war veterans with and without posttraumatic stress disorder. <i>Journal of Affective Disorders</i> , 2003, 75, 171-179.	4.1	21
67	Olanzapine in the treatment-resistant, combat-related PTSD - a series of case reports. <i>Acta Psychiatrica Scandinavica</i> , 2003, 107, 394-396.	4.5	67
68	Long-term sertraline treatment and peripheral biochemical markers in female depressed patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 759-765.	4.8	33
69	Effects of Sertraline Treatment on Plasma Cortisol, Prolactin and Thyroid Hormones in Female Depressed Patients. <i>Neuropsychobiology</i> , 2002, 45, 139-143.	1.9	47
70	Efficacy and safety of long-term risperidone treatment. <i>International Journal of Psychiatry in Clinical Practice</i> , 2002, 6, 193-197.	2.4	2
71	The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2002, 26, 1235-1243.	4.8	62
72	Platelet serotonergic markers in posttraumatic stress disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2002, 26, 1193-1198.	4.8	19